NYSE:ITGR - Integer Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $107.00
  • Forecasted Upside: 38.80 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$77.09
▲ +0.48 (0.63%)

This chart shows the closing price for ITGR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Integer Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ITGR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ITGR

Analyst Price Target is $107.00
▲ +38.80% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Integer in the last 3 months. The average price target is $107.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 38.80% upside from the last price of $77.09.

This chart shows the closing price for ITGR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Integer. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/28/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/29/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/27/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/25/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/23/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/24/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/1/2022KeyCorpLower Price TargetOverweight$111.00 ➝ $109.00High
10/29/2021KeyCorpBoost Price TargetOverweight$107.00 ➝ $111.00High
9/13/2021ArgusBoost Price TargetBuy$100.00 ➝ $105.00Medium
7/30/2021KeyCorpBoost Price TargetOverweight$105.00 ➝ $107.00Medium
6/9/2021ArgusUpgradeHold ➝ Buy$100.00Low
10/30/2020KeyCorpLower Price TargetOverweight$87.00 ➝ $85.00High
10/7/2020ArgusDowngradeBuy ➝ HoldHigh
5/14/2020BenchmarkInitiated CoverageBuy$105.00Low
5/8/2020SidotiBoost Price TargetBuy$100.00 ➝ $108.00High
5/8/2020KeyCorpLower Price TargetOverweight$90.00 ➝ $87.00High
4/13/2020KeyCorpLower Price TargetOverweight$116.00 ➝ $90.00High
2/21/2020KeyCorpBoost Price TargetOverweight$97.00 ➝ $116.00Medium
8/2/2019Northcoast ResearchReiterated RatingBuyHigh
6/5/2019ArgusLower Price TargetBuy ➝ Average$90.00 ➝ $4.29Low
2/25/2019Royal Bank of CanadaBoost Price TargetSector Perform ➝ Sector Perform$84.00 ➝ $92.00Low
11/2/2018Royal Bank of CanadaBoost Price Target$84.00Low
11/2/2018KeyCorpBoost Price TargetOverweight ➝ Overweight$81.00 ➝ $93.00Low
8/3/2018Royal Bank of CanadaReiterated RatingHold$72.00High
7/20/2018Northcoast ResearchUpgradeBuy$83.00Low
7/13/2018Northcoast ResearchUpgradeNeutral ➝ BuyMedium
7/6/2018KeyCorpReiterated RatingOverweight ➝ Overweight$65.00 ➝ $78.00Medium
6/27/2018ArgusInitiated CoverageBuy$78.00Medium
5/4/2018KeyCorpBoost Price TargetOverweight ➝ Overweight$60.00 ➝ $62.00Low
10/27/2017Royal Bank of CanadaReiterated RatingHold ➝ NeutralN/A
10/23/2017Northcoast ResearchDowngradeBuy ➝ NeutralN/A
9/22/2017Royal Bank of CanadaReiterated RatingHold$40.00Low
9/18/2017KeyCorpReiterated RatingOverweight$51.00 ➝ $62.00High
(Data available from 5/25/2017 forward)

News Sentiment Rating

0.16 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
10/27/2021
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/26/2021
  • 6 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
12/26/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/25/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
2/24/2022
  • 1 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/26/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
4/25/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
5/25/2022

Current Sentiment

  • 2 very positive mentions
  • 6 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Integer logo
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through Medical and Non-Medical segments. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and power management systems, and battery solutions for the energy, military, and environmental markets. Furthermore, the company provides medical technologies. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.
Read More

Today's Range

Now: $77.09
Low: $75.24
High: $77.36

50 Day Range

MA: $78.52
Low: $70.96
High: $87.38

52 Week Range

Now: $77.09
Low: $68.58
High: $101.61

Volume

166,181 shs

Average Volume

187,543 shs

Market Capitalization

$2.55 billion

P/E Ratio

29.65

Dividend Yield

N/A

Beta

1.28

Frequently Asked Questions

What sell-side analysts currently cover shares of Integer?

The following Wall Street research analysts have issued research reports on Integer in the last year: Argus, KeyCorp, StockNews.com, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for ITGR.

What is the current price target for Integer?

0 Wall Street analysts have set twelve-month price targets for Integer in the last year. Their average twelve-month price target is $107.00, suggesting a possible upside of 38.8%.
View the latest price targets for ITGR.

What is the current consensus analyst rating for Integer?

Integer currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ITGR will outperform the market and that investors should add to their positions of Integer.
View the latest ratings for ITGR.

How do I contact Integer's investor relations team?

Integer's physical mailing address is 5830 Granite Parkway Suite 1150, Plano TX, 75024. The medical equipment provider's listed phone number is (214) 618-5243 and its investor relations email address is [email protected] The official website for Integer is www.integer.net. Learn More about contacing Integer investor relations.